Patient info Open main menu

Lansoprazole 15 mg orodispersible tablets – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
15 mg
Contains active substance:

Patient leaflet - Lansoprazole 15 mg orodispersible tablets

1. What Lansoprazole orodispersible tablets is and what it is used for

The active ingredient in Lansoprazole 15mg and 30mg oro-dispersible tablets is lansoprazole, which is a proton pump inhibitor. Proton pump inhibitors reduce the amount of acid that your stomach makes. Your doctor may prescribe Lansoprazole oro-dispersible tablets for the following indications:

  • Treatment of duodenal and stomach ulcer
  • Treatment of inflammation in your oesophagus (reflux oesophagitis)
  • Prevention of reflux oesophagitis
  • Treatment of heartburn and acid regurgitation
  • Treatment of infections caused by the bacteria Helicobacter pylori

    when given in combination with antibiotic therapy

  • Treatment or prevention of duodenal or stomach ulcer in patients

    requiring continued non-steroidal anti-inflammatory drugs (NSAID) treatment (NSAID treatment is used against pain or inflammation)

  • Treatment of Zollinger-Ellison syndrome.

Your doctor may have prescribed Lansoprazole oro-dispersible tablets for another indication or with a dose different from that which is written in this information leaflet. Please take your medicine in consultation with your doctor.

You must talk to a doctor if you do not feel better or if you feel worse after 14 days.

2. What you need to know before you take Lansoprazole oro-dispersible tablets

Do not take Lansoprazole oro-dispersible tablets:

  • if you are allergic to lansoprazole or any of the other ingredients of this

    medicine (listed in section 6).

Warnings and precautions

Please tell your doctor if you have serious liver disease. The doctor may have to adjust your dosage.

Your doctor may perform or have performed an additional investigation called an endoscopy in order to diagnose your condition and/or exclude malignant disease.

If severe or persistent diarrhoea occurs during the treatment with Lansoprazole oro-dispersible tablets contact your doctor immediately, as Lansoprazole oro-dispersible tablets have been associated with a small increase in infectious diarrhoea.

If your doctor has given you Lansoprazole oro-dispersible tablets in addition to other medicines intended for the treatment of Helicobacter pylori infection (antibiotics) or together with anti-inflammatory medicines to treat your pain or rheumatic disease: please also read the package leaflets of these medicines carefully.

If you take Lansoprazole oro-dispersible tablets for more than three months it is possible that the levels of magnesium in your blood may fall.

Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness, increased heart rate. If you get any of these symptoms, please tell your doctor promptly. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood. Your doctor may decide to perform regular blood tests to monitor your levels of magnesium.

Taking a proton pump inhibitor like Lansoprazole oro-dispersible tablets, especially over a period of more than one year, may slightly increase your risk of fracture in the hip, wrist or spine. Tell your doctor if you have osteoporosis (reduced bone density) or if your doctor has told you are risk of getting osteoporosis (for example, if you are taking steroids). This medicine may affect the way that your body absorbs vitamin B12, particularly if you need to take it for a long time. Please contact your doctor if you notice any of the following symptoms, which could indicate low levels of Vitamin B12:

  • Extreme tiredness or lack of energy
  • Pins and needles
  • Sore or red tongue, mouth ulcers
  • Muscle weakness
  • Disturbed vision
  • Problems with memory, confusion, depression

If you take Lansoprazole oro-dispersible tablets on a long-term basis (longer than 1 year) your doctor will probably keep you under regular surveillance. You should report any new and exceptional symptoms and circumstances whenever you see your doctor.

Talk to your doctor before taking Lansoprazole oro-dispersible tablets:

  • if you are due to have a specific blood test (Chromogranin A).
  • if you have ever had a skin reaction after treatment with a medicine

    similar to lansoprazole oro-dispersible tablets that reduces stomach acid.

Serious skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in association with lansoprazole treatment. Stop using Lansoprazole oro-dispersible tablets and seek medical attention immediately if you notice any of the symptoms described in section 4.

If you get a rash on your skin, especially in areas exposed to the sun tell your doctor as soon as you can, as you may need to stop your treatment with lansoprazole oro-disperisble tablets. Remember to also mention any other ill-effects like pain in your joints.

When taking lansoprazole, inflammation in your kidney may occur. Signs and symptoms may include decreased volume of urine or blood in your urine and/or hypersensitivity reactions such as fever, rash, and joint stiffness. You should report such signs to the treating physician. Other medicines and Lansoprazole oro-dispersible tablets

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

In particular tell your doctor or pharmacist if you are taking medicines containing any of the following active substances as Lansoprazole oro-dispersible tablets may affect the way these medicines work: § HIV protease inhibitors such as atazanavir and nelfinavir (used to treat

HIV)

§ methotrexate (used to treat autoimmune disease and cancer) § ketoconazole, itraconazole, rifampicin (used to treat infections) § digoxin (used to treat heart problems)

§ warfarin (used to treat blood clots)

§ theophylline (used to treat asthma)

§ tacrolimus (used to prevent transplant rejection)

§ fluvoxamine (used to treat depression and other psychiatric diseases) § antacids (used to treat heartburn or acid regurgitation) § sucralfate (used for healing ulcers)

§ St John's wort (Hypericum perforatum) (used to treat mild

depression)

Lansoprazole oro-dispersible tablets with food and drink

For the best results from your medicines, you should take Lansoprazole oro-dispersible tablets at least 30 minutes before food.

Pregnancy, breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Driving and using machines

Side effects such as dizziness, vertigo, tiredness and visual disturbances sometimes occur in patients taking Lansoprazole oro-dispersible tablets. If you experience side effects like these, you should take caution as your ability to react may be decreased.

You alone are responsible to decide if you are in a fit condition to drive a motor vehicle or perform other tasks that demand increased concentration. Because of their effects or undesirable effects, one of the factors that can reduce your ability to do these things safely is your use of medicines.

Descriptions of these effects can be found in other sections. Read all the information in this leaflet for guidance.

Discuss with your doctor or pharmacist if you are unsure about anything. Lansoprazole oro-dispersible tablets contains aspartame

Lansoprazole oro-dispersible tablets contain aspartame. Aspartame is a source of phenylalanine. Phenylalanine may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.

3. How to take Lansoprazole oro-dispersible tablets

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

Place the tablet on your tongue and suck gently. The tablet rapidly dissolves in the mouth, releasing pellets which you should swallow without chewing. You can also swallow the tablet whole with a glass of water.

Your doctor might instruct you to take the tablet with a syringe in case you have serious difficulties with swallowing.

The following instructions should be followed if administered via syringe: It is important that the appropriateness of the selected syringe is carefully tested.

§ Remove the plunger of the syringe (at least 5 ml syringe for the 15 mg tablet and 10 ml syringe for the 30 mg tablet)

§ Put the tablet into the barrel

§ Put the plunger back onto the syringe

§ For the 15 mg tablet: Draw 4 ml tap water into the syringe § For the 30 mg tablet: Draw 10 ml tap water into the syringe § Invert the syringe and draw an additional 1 ml of air into it § Shake the syringe gently for 10-20 seconds until the tablet is dispersed

§ The contents can be emptied directly into the mouth

§ Refill the syringe with 2 ml - 5 ml of tap water to flush the remnants out of the syringe into the mouth.

If you are taking Lansoprazole oro-dispersible tablets once a day, try to take it at the same time each day. You may get best results if you take Lansoprazole oro-dispersible tablets first thing in the morning. If you are taking Lansoprazole oro-dispersible tablets twice a day, you should have the first dose in the morning and the second dose in the evening.

The dose of Lansoprazole oro-dispersible tablets depends on your condition. The usual doses of Lansoprazole oro-dispersible tablets for adults are given below. Your doctor will sometimes prescribe you a different dose and will tell you how long your treatment will last. Treatment of heartburn and acid regurgitation: one 15 mg or 30 mg oro-dispersible tablet every day for 4 weeks. If your symptoms are not relieved within 4 weeks, please contact your doctor.

Treatment of duodenal ulcer: one 30 mg oro-dispersible tablet every day for 2 weeks

Treatment of stomach ulcer: one 30 mg oro-dispersible tablet every day for 4 weeks

Treatment of inflammation in your oesophagus (reflux oesophagitis):

one 30 mg oro-dispersible tablet every day for 4 weeks

275260 LFLT LANSOPRZOL OD TABS UK R9 (FRONT)

Market/Customer :UKLocation :Pithampur
Prepared On :09/12/2023Tracking No. :04
Product Name :LFLT LANSOPRZOL OD TABS UK R9
Material Code :275260272560
350 x 235 mm (L x W)9179
Folded Size :60 x 30 mm ( (L x W)NA
Substrate :

GSM : 40 gsm

Paper : Bible Paper

Pack Insert
Gluing :Yes
Font Name :Helvetica CondensedPerforation :NA
9 ptCover Page Substrate :NA
Reason for Change :Change in textmatter as per customer requirement

Long-term prevention of reflux oesophagitis: one 15 mg oro-dispersible tablet every day, your doctor may adjust your dose to one 30 mg oro-dispersible tablet every day.

Treatment of infection of Helicobacter pylori: The usual dose is one 30 mg oro-dispersible tablet in combination with two different antibiotics in the morning and one 30 mg oro-dispersible tablet in combination with two different antibiotics in the evening. Treatment will usually be every day for 7 days.

The recommended combinations of antibiotics are:

§ 30 mg Lansoprazole oro-dispersible tablets together with 250-

500 mg clarithromycin and 1000 mg amoxicillin

§ 30 mg Lansoprazole oro-dispersible tablets together with 250 mg

clarithromycin and 400- 500 mg metronidazole

If you are being treated for infection because you have an ulcer, it is unlikely that your ulcer will return if the infection is successfully treated. To give your medicine the best chance of working, take it at the right time and do not miss a dose.

Treatment of duodenal or stomach ulcer in patients requiring continued NSAID treatment: one 30 mg oro-dispersible tablet every day for 4 weeks. Prevention of duodenal or stomach ulcer in patients requiring continued NSAID treatment: one 15 mg oro-dispersible tablet every day, your doctor may adjust your dose to one 30 mg oro-dispersible tablet every day.

Zollinger-Ellison syndrome: The usual dose is two 30 mg oro-dispersible tablets every day to start with, then depending on how you respond to Lansoprazole oro-dispersible tablets the dose that your doctor decides is best for you.

Use in children

Lansoprazole oro-dispersible tablets should not be given to children. If you take more Lansoprazole oro-dispersible tablets than you should

If you take more Lansoprazole oro-dispersible tablets than you have been told to, seek medical advice quickly.

If you forget to take Lansoprazole oro-dispersible tablets

If you forget to take a dose, take it as soon as you remember unless it is nearly time for your next dose. If this happens skip the missed dose and take the remaining oro-dispersible tablets as normal. Do not take a double dose to make up for a forgotten oro-dispersible tablet.

If you stop taking Lansoprazole oro-dispersible tablets

Do not stop treatment early because your symptoms have got better. Your condition may not have been fully healed and may reoccur if you do not finish your course of treatment.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. If you think you may have any of the following serious side effects, stop taking this medicine and contact your doctor or go to your nearest hospital emergency room immediately.

  • Very rarely lansoprazole may cause severe hypersensitivity (allergic)

    reactions. Symptoms of a hypersensitivity reaction may include fever, rash, swollen face, swollen lymph nodes, swollen tongue or pharynx, difficulty to swallow, hives, difficulty to breath and sometimes a fall in blood pressure.

  • Very rarely, severe skin reactions that may be life threatening have

    been reported with Lansoprazole. Symptoms include reddish patches on the trunk, the patches are target-like macules or circular, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes. These serious skin rashes can be preceded by fever and flu-like symptoms [Stevens-Johnsons Syndrome (SJS), Toxic Epidermal Necrolysis (TEN)].

  • Widespread rash, high body temperature and enlarged lymph nodes

    [Drug Reaction with Eosinophilia and Systemic Systems (DRESS, frequency not known)].

  • If you take Lansoprazole oro-dispersible tablets for more than three

    months it is possible that the levels of magnesium in your blood may fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness, increased heart rate. If you get any of these symptoms, please tell your doctor promptly. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood. Your doctor may decide to perform regular blood tests to monitor your levels of magnesium.

    • Very rarely lansoprazole may cause a reduction in the number of white

      blood cells (agranulocytosis) and your resistance to infection may be decreased or coexisting abnormal reductions in the number of red and white blood cells, as well as platelets (pancytopenia). If you experience an infection with symptoms such as fever and serious deterioration of your general condition, or fever with local infection symptoms such as sore throat/pharynx/mouth or urinary problems, or experience tiredness, pale skin with unexplained bruising or bleeding for longer than normal, you should see your doctor immediately. A blood test will be taken to check possible reduction of blood cells.

    • Rarely lansoprazole may cause inflammation of the pancreas

      (pancreatitis) and its symptoms include sudden intense pains in the middle of the upper abdomen that may radiate to the back, which may lead to nausea and vomiting.

    • If severe or persistent diarrhoea occurs during the treatment with

      Lansoprazole oro-dispersible tablets contact your doctor immediately, as lansoprazole has been associated with a small increase in infectious diarrhoea.

Other possible side effects:

Common: may affect up to 1 in 10 people:

§ headache, dizziness

§ constipation, stomach pains, feeling or being sick, wind, dry or sore

mouth or throat

§ skin rash, itching

§ changes in liver function test values

§ tiredness

§ benign polyps in the stomach

Uncommon: may affect up to 1 in 100 people:

§ depression

§ joint or muscle pain

§ fluid retention or swelling

§ changes in blood cell counts

§ risk of hip, wrist and spine fracture

Rare: may affect up to 1 in 1000 people:

§ fever

§ restlessness, drowsiness, confusion, hallucinations, insomnia, visual

disturbances, vertigo

§ a change in the way things taste, loss of appetite, inflammation of your

tongue (glossitis)

§ skin reactions such as burning or pricking feeling under the skin,

bruising, reddening and excessive sweating

§ sensitivity to light

§ hair loss

§ feelings of ants creeping over the skin (paraesthesia), trembling § anaemia (paleness)

§ inflammation of the kidneys (tubulointerstitial nephritis), possible

symptoms include changes in amount of urine, blood in urine § inflammation of the liver (may be seen as yellow skin or eyes) § breast swelling in males, impotence

§ candidiasis (fungal infection, may affect esophagus mucosa) Very rare: may affect up to 1 in 10000 people:

§ inflammation of your mouth (stomatitis)

§ bowel inflammation (colitis)

§ increase in test values such as cholesterol and triglyceride levels § low levels of sodium in the blood, symptoms include nausea and

vomiting, headache, drowsiness and fatigue, confusion, muscle weakness or spasms, irritability, seizures, coma. Your doctor may decide to perform regular blood tests to monitor your levels of sodium.

Not known: frequency cannot be estimated from the available data § skin related forms of lupus or lupus rash

§ rash, possibly with pain in the joints

§ visual hallucinations

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store Lansoprazole orodispersible tablets

Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the blister and carton. The expiry date refers to the last day of that month. Do not store above 25°C. Keep your medicine in the packaging that it came in to help protect it from moisture.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information What Lansoprazole orodispersible tablets contain

  • The active substance is lansoprazole. One (1) 15mg oro-dispersible tablet contains 15mg of lansoprazole, one (1) 30mg oro-dispersible tablet contains 30mg of lansoprazole.
  • The other ingredients are microcrystalline cellulose, light magnesium carbonate, low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose (E463), hypromellose 3 cps (E464), talc (E553b), titanium dioxide (E171), mannitol (E421), methacrylic acid ethyl acrylate copolymer dispersion (1:1), polyacrylate dispersion, glycerol monostearate, polyethylene glycol 6000, triethyl citrate, polysorbate 80, anhydrous citric acid (E330), ferric oxide yellow (E172), ferric oxide red (E172), F-melt type C, crospovidone, aspartame (E951), strawberry flavour, magnesium stearate.

What Lansoprazole oro-dispersible tablets look like and contents of the pack

Lansoprazole 15mg and 30mg oro-dispersible tablets are white to yellowish white uncoated tablets, speckled with orange to dark brown pellets. Lansoprazole 15mg oro-dispersible tablets are debossed with “I5” on one side of the tablet and Lansoprazole 30mg oro-dispersible tablets are debossed with “30” on one side of the tablet. Each Lansoprazole 15mg and 30mg oro-dispersible tablet is strawberry flavoured. Lansoprazole 15mg and 30mg oro-dispersible tablets are available in packs of 7, 14, 28, 56, and 98 tablets.

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Lupin Healthcare (UK) Limited

The Urban Building, 2nd floor,

3-9 Albert Street, Slough, Berkshire,

SL1 2BE, United Kingdom.

This medicinal product is authorised in the Member States of the EEA under the following names:

United Kingdom: Lansoprazole 15mg and 30mg Orodispersible Tablets This leaflet was last revised in 12/2023.

Code No. MP/DRUGS/25/8/2010 ID#: 275260

275260 LFLT LANSOPRZOL OD TABS UK R9 (BACK)

Market/Customer :UKLocation :Pithampur
Prepared On :09/12/2023Tracking No. :04
Product Name :LFLT LANSOPRZOL OD TABS UK R9
Material Code :275260272560
350 x 235 mm (L x W)9179
Folded Size :60 x 30 mm ( (L x W)NA
Substrate :

GSM : 40 gsm

Paper : Bible Paper

Pack Insert
Gluing :Yes
Font Name :Helvetica CondensedPerforation :NA
9 ptCover Page Substrate :NA
Reason for Change :Change in textmatter as per customer requirement

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 35507/0118

Last revision stated in the text: December 2023 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Lansoprazole 15 mg orodispersible tablets

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Lansoprazole
Strength 15 mg
Pharmaceutical form Orodispersible tablet
How is it taken Oral
Pack sizes 28 tablet
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Drug group (ATC)
  1. A Alimentary tract and metabolism drugs
    1. A02 Drugs for acid related disorders
      1. A02B Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
        1. A02BC Proton pump inhibitors for peptic ulcer and GORD
          1. A02BC03 lansoprazole
Marketing authorisation PL 35507/0118
Codes GTIN 5015525123528, 5060346430294 · BNF 01030500

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.